Mithra will receive a milestone payment of 2.5 million euros from Fuji Pharma under the license agreement for ESTELLE®
• This payment will follow the submission of an application for marketing authorization in Japan
• It marks a major step forward in the implementation of the 2016 agreement and strengthens Mithra’s cash position
• Additional milestone payments of €10 million expected following approval of marketing authorization
• Mithra may receive income linked to the supply of the manufactured product, from the time it is placed on the market
Liège, Belgium, October 23, 2023 – 7:00 a.m. CEST – Mithra (Euronext Brussels: MITRA), a women’s health company, today announces that its licensee Fuji Pharma Co., Ltd. has submitted an application for marketing approval in Japan for its ESTELLE® product to combat dysmenorrhea. This request for approval marks another important milestone in the agreement under which Mithra will receive a milestone payment of €2.5 million.